302 results
6-K
EX-99.1
BNTX
BioNTech SE
3 Jun 24
Current report (foreign)
7:46am
to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates … opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research
6-K
EX-99.1
BNTX
BioNTech SE
29 May 24
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
7:21pm
research, development and rapid manufacturing of mRNA vaccines. This will contribute to Africa’s resilience and pandemic readiness and could dramatically … mRNA research and development, clinical and commercial-scale manufacturing capabilities at its facility in Kigali; BioNTech’s ongoing and future planned
6-K
EX-99.1
BNTX
BioNTech SE
21 May 24
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
4:36pm
, but not be limited to, statements concerning: the initiation, timing, progress and results of BioNTech’s research and development programs in oncology, including … to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion
6-K
EX-99.1
BNTX
BioNTech SE
17 May 24
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
4:10pm
to, statements concerning BioNTech’s financial position; BioNTech’s research and development programs, including statements characterizing timing
6-K
EX-99.2
BNTX
BioNTech SE
17 May 24
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
4:10pm
or sublineages; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current … solutions; and BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital
6-K
EX-99.1
8spssbzf 3o1
6 May 24
Current report (foreign)
7:18am
6-K
EX-99.2
otudzbvfjgfyjo
6 May 24
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
6:48am
6-K
EX-99.1
phsrhj96zk4 h5z4bs
6 May 24
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
6:48am
6-K
EX-99.1
m759ctbcs31lx1gn
8 Apr 24
Invitation to the Annual General Meeting 2024
5:05pm
6-K
EX-99.1
a8ohcng6t 0j
8 Apr 24
Current report (foreign)
7:12am
6-K
EX-99.1
nac7c4b26t tw68rn
11 Mar 24
BioNTech to Present Clinical Data Updates For Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
9:04am
6-K
EX-99.1
voh yx45g5wer5s
7 Mar 24
BioNTech Announces Planned Retirement of Sean Marett
8:41am
S-8
EX-4.1
uybwcz1e4gqv1g2ub
15 Feb 24
Registration of securities for employees
4:10pm
6-K
EX-99.1
r6wxpey4
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:08am
6-K
EX-99.1
v7u4iff0c
31 Jan 24
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
7:47am
6-K
EX-99.1
qrjw mxkr1b09x95a7z
22 Jan 24
Current report (foreign)
9:14am
6-K
EX-99.2
4gizb 10k6lx59v0nidr
9 Jan 24
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
7:01am
6-K
EX-99.1
sduafeifagwhkwel wl
9 Jan 24
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
7:01am
6-K
EX-99.1
g4j1puw3
21 Dec 23
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
4:02pm
6-K
EX-99.1
igjvz5gn
18 Dec 23
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
4:22pm